MAGEA3 and melanoma: In 2015, BioNTech initiated a multicenter, open-label, dose-escalation phase I trial (Lipo-MERIT, NCT02410733) to assess the efficiency and safety of FixVac (BNT111), which is composed of RNA-LPX encoding NY-ESO-1, MAGE-A3, TPTE, and tyrosinase, for the treatment of advanced melanoma patients [168].